Media

Bayer launches Grants4AppsToronto

Three digital health startups, 88 days and a once in a lifetime opportunity to be mentored by a global leader in life sciences

TORONTO, ON (April 11, 2017) - Grants4Apps®Toronto, a new incubator program from Bayer, is now accepting applications for digital health solutions that will help facilitate the work of Canadian healthcare professionals and improve the lives of Canadians. Grants4AppsToronto connects digital health startups with industry experts through mentoring and coaching, financial support up to $10,000 per startup and networking opportunities. The three Grants4Apps finalists will also get office space from June 5 to October 4, 2017 at Bayer’s Canadian headquarters in Mississauga.

“We are excited to bring the Grants4Apps global program to Toronto because the digital space in the healthcare industry is still emerging and the possibilities for innovative applications are endless,” said Shurjeel Choudri, Head of Medical & Scientific Affairs, Bayer Inc., “We need to continually explore technologies, foster innovation and support Canadian startups. As a global leader in life sciences, our experience in healthcare, regulatory and marketing will benefit these three digital startups with invaluable expertise to help them successfully get their solution off the ground.”

Grants4AppsToronto is looking for applications from startups beyond the ideation phase developing health technology or innovative solutions focusing on digital health solutions that augment the following areas of focus:

Cardiovascular

Ophthalmology

Oncology

Pulmonary Hypertension

Women’s Healthcare,

Consumer Health (pain, allergy, footcare, sun protection)

Companion Health (animals and pets)

The global program started in 2012 in Berlin and has expanded to seven countries. This is the first year for a Canada-specific Grants4Apps program. The program is open to legal entities based in Canada and individual Canadians who are 18 years old or older. The Grants4AppsToronto application period opens from April 11, 2017 to April 30, 2017.

Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2016, the Group employed around 115,200 people and had sales of EUR 46.8 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.7 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.ca.

Media Contact:

Rowena Calpito Tel: 905-282-5870

E-mail: rowena.calpito@bayer.com

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.